Abstract: The present invention relates to methods for treating or preventing viral infection, or disease or complications associated with viral infection, in particular infection by a coronavirus or influenza virus, optionally SARS-CoV-2, SARS-CoV or MERS-CoV.

Abstract: The invention relates to agents capable of sensitising STING activation, compositions comprising said agents and medical uses thereof. The agents may be peptides and compositions thereof. Methods of treatment of a disease or disorder, for instance cancer, by administration of the agents of the invention to a subject in need thereof is also provided.

Abstract: Compounds capable of mimicking the pyrin-domain of IF116 is provided together with compounds capable of binding to the pyrin-domain of IF116 or a fragment thereof as well as their uses in medicine. Specifically, the compounds are provided for use in the treatment of disorders associated with STING activity, including cancer and immuno-deficient or auto-immune disorders.

Abstract: HSPC-derived Plasmacytoid dendritic cells (HSPC-pDCs) constitute a rare type of immune cell with multifaceted functions that bridge pivotal pants of the immune system. Biological studies of blood-derived HSPC-pDCs and their potential use as a cell-based immunotherapy have long been challenged by the scarce amounts of HSPC-pDCs that can be extracted from blood samples. This invention is related to a process for HSPC-pDC production applicable for clinical use, which involves in vitro differentiation of hematopoietic stem and progenitor cells (HSPCs). With this optimized GMP-compliant protocol, we generated an average of 465 million HSPC-derived pDCs (HSPC-pDCs) starting from 100,000 cord-blood derived HSPCs, and we also show that the protocol enables robust HSPC-pDC generation from HSPCs extracted from whole blood. The produced cells display a pDC phenotype (Lin?/CD11c?/CD123+/CD303+) and the ability to produce high levels of type I interferon upon TLR7 and TLR9 stimulation.

Abstract: The present invention relates to methods for treating disease, in particular cancer and autoimmune and inflammatory diseases, using engineered cells.

Abstract: Compounds capable of mimicking the pyrin-domain of IF116 is provided together with compounds capable of binding to the pyrin-domain of IF116 or a fragment thereof as well as their uses in medicine. Specifically, the compounds are provided for use in the treatment of disorders associated with STING activity, including cancer and immuno-deficient or auto-immune disorders.

Abstract: Modified polypeptides derived from the pyrin-domain of IFI16 are provided as well as their uses in medicine. Specifically, the polypeptides are provided for use in the treatment of disorders associated with STING activity, including cancer and immunodeficient or auto-immune disorders.

Abstract: The present invention relates to the use of a composition comprising a helminth product for prevention, treatment and/or amelioration of a clinical condition associated with the RIG-LISTING and TLR pathways. Specifically, the composition is provided for use in the treatment of clinical conditions associated with constitutive activation of type I interferon (IFN), including monogenic type I interferonopathies and inflammatory or autoimmune disorders. The present invention also relates to different methods of manufacturing a helminth product.

Abstract: The present invention relates to tools for modulating the P62-STING interaction as a method for modulating the innate immune response. The invention relates to compounds which are capable of either inhibiting or potentiating the interaction and thereby induce or prevent the innate immune response relating to STING. Specifically, compounds are provided for use in the treatment of disorders associated with STING activity, including cancer and immuno-deficient or auto-immune disorders.

Abstract: Modified polypeptides derived from the pyrin-domain of IFI16 are provided as well as their uses in medicine. Specifically, the polypeptides are provided for use in the treatment of disorders associated with STING activity, including cancer and immunodeficient or auto-immune disorders.

Abstract: A method is provided for producing a plasmacytoid dendritic cells (pDCs), wherein hematopoietic stem and progenitor cells (HSPCs) are provided and incubated in a first medium comprising cytokines and growth factor whereby the HSPCs are differentiated into precursor-pDCs and then adding interferons (IFNs) to the first medium to obtain a second medium whereby said precursor-pDCs are differentiated into pDCs. Furthermore, a technique is provided for producing genetically modified pDCs, by initially genetically modifying HSPCs using transfection methods, including electroporation, to deliver sgRNA and Cas9 protein Moreover, a pharmaceutical formulation and a vaccine is provided which comprises pDC or genetically modified pDCs obtained according to that method.

Abstract: Compounds capable of mimicking the pyrin-domain of IFI16 is provided together with compounds capable of binding to the pyrin-domain of IFI16 or a fragment thereof as well as their uses in medicine. Specifically, the compounds are provided for use in the treatment of disorders associated with STING activity, including cancer and immuno-deficient or auto-immune disorders.